Articles from Eurofins Scientific

Eurofins Viracor BioPharma Services, a long‑standing and trusted partner for clinical trial testing solutions with deep expertise in specialty biomarkers and molecular assays, announces a significant expansion of its service portfolio with the addition of enhanced bioanalytical testing capabilities. These new services are fully aligned with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), enabling the company to enhance support of biopharmaceutical development programs with greater scientific breadth throughout the drug development workflow.

Eurofins Viracor BioPharma Services, a recognized leader in analytical testing and clinical trial services, announces the infrastructure enhancement of its headquarters and laboratory operations to a new, custom-built 96,000 sq. ft. facility in Lenexa, Kansas, scheduled for completion in September 2025. This strategic move, although only a few miles from its previous location, marks a significant milestone in the company’s continued growth and commitment to delivering cutting-edge solutions to the biopharmaceutical industry.

Eurofins MTS Consumer Product Testing US, based in Norwood, Boston MA, has completed a significant expansion, doubling total laboratory space, increasing workforce by 30% and adding three new specialised laboratories focused on Softlines & Hardlines, Furniture, and Toys. Eurofins MTS Consumer Product Testing US joined the international network of Eurofins laboratories in 2021 and is a full-service safety, quality, and sustainability service provider for retailers, brands, and manufacturers of consumer products.

Eurofins EAG Laboratories, a global leader in materials testing services, is expanding its battery materials testing capabilities with a new purpose-built 6,600 square-foot laboratory located in Sunnyvale, CA. and expanded facilities at its Syracuse, New York laboratory with the addition of 6,500 square-foot of new laboratory space.

Regulatory News:

Eurofins J3 Resources, part of Eurofins Built Environment Testing US, is proud to announce it has been granted AIHA LAP, LLC accreditation as part of a National expansion program of Industrial Hygiene credentials. Eurofins J3 Resources’ industrial hygiene service offering to Texas, Louisiana and Gulf Coast based refineries and chemical plants has been extended to now include rapid turnaround time, media/pump supplies and on-staff Certified Industrial Hygienists.

Eurofins CDMO Alphora Inc. announces receipt in April 2022 of its Health Canada Standard Processing License issued within the Cannabis Act and Cannabis Regulations for its Oakville, Ontario Operations. This is complementary to the Institutional Research License obtained through Health Canada in June 2021 for its Mississauga development site.

Eurofins Scientific (“Eurofins”) (Paris:ERF), a global scientific leader in bioanalytical testing and clinical diagnostics testing, announces that its subsidiary, Eurofins Clinical Testing Lux Sarl, has acquired Genetic Testing Service JSC (“Gentis”), a pioneer in genetic testing in Vietnam. The acquisition will further enhance Eurofins’ expansion in Asia and complement its global network of clinical diagnostics laboratories focused on specialised and advanced genetic testing.

For a number of months now, Eurofins Scientific (Paris:ERF) has been monitoring wastewater in Denmark for the presence of SARS-CoV-2, through the regular (3 times per week) sampling of around 200 wastewater treatment plants across the country. Wastewater is an effective mirror of society, and wastewater testing is acknowledged as a way to monitor the virus’ spread and to detect new variants early, often before the first clinical cases are known.

Eurofins Environment Testing adds Omicron variant detection capabilities to its commercially available SARS-CoV-2 test portfolio. The Omicron variant has been identified as a ‘variant of concern’ by the World Health Organization (WHO) due to the high number of mutations in the spike protein and indications of high transmissibility.

Second paragraph, second sentence of release should read: "which includes the initial EPA PFAS" (instead of "which includes the initial EPA FAS").

Eurofins Eaton Analytical is prepared for UCMR5 testing in advance of anticipated rule release.

The United States District Court for District of Delaware has ruled that the patent asserted in CareDx’s patent infringement case against Eurofins Viracor is invalid. Eurofins Viracor is very pleased that the Court has agreed with its arguments and issued judgment in Eurofins Viracor’s favor in this challenge to Eurofins’ critically important diagnostic tools to manage organ rejection risk.

Transplant Genomics (“TGI”), the transplant rejection diagnostics company committed to improving organ transplant outcomes worldwide, is pleased to introduce OmniGraf™, which combines the TruGraf® blood gene expression test and Viracor TRAC® donor-derived cell-free DNA assays. For renal transplant recipients, OmniGraf™ Kidney represents the first diagnostic tool that combines cell free DNA and gene expression data. When combined with TGI’s proprietary technology and machine learning, the test offers patients the earliest and most accurate view of kidney transplant rejection.

Eurofins (Paris:ERF), through its empowerDX subsidiary, and Rite Aid announce the launch of an over-the-counter, FDA-authorised[1], at-home COVID-19 PCR Test Kit. The co-branded kits, available at all Rite Aid stores across 17 states in the USA, will offer customers a convenient way to test for the virus from their home and will detect the virus in symptomatic and asymptomatic patients.

As one of the first commercial labs to deliver COVID-19 testing, Eurofins Viracor, Inc. continues to innovate with the launch of Coronavirus SARS-CoV-2 inSIGHT™ T Cell Immunity testing. Viracor’s inSIGHT™ T Cell Immunity test delivers an understanding of a patient's response to viral antigens providing critical insight to aid in treatment decisions. The test measures CD4+ and CD8+ T Cell response to the SARS-CoV-2 spike (S) and nucleocapsid (N) proteins to independently evaluate cell-mediated immunity to Coronavirus SARS-CoV-2 that causes COVID-19.

Eurofins Scientific (“Eurofins”), a global scientific leader in bioanalytical testing, announces that its subsidiary Eurofins Clinical Testing US Holdings, Inc. has entered into an agreement to acquire DNA Diagnostics Center (“DDC”), a leader in consumer genetic testing. DDC anticipates delivering revenues of over US$55m in 2021.

Clinical Enterprise, Inc., a Eurofins Scientific company, today announced it has been awarded a U.S. Government agreement to expand national COVID-19 testing. The agreement with the U.S. Department of Health and Human Services, in coordination with the U.S. Department of Defense (DOD), will expand testing opportunities in K-8 schools, underserved populations and congregate settings such as homeless shelters. Eurofins has been awarded the agreement to test up to 24.6 million people in the Northeast and South regions.

Eurofins (Paris:ERF) subsidiary, empowerDX, today announced that it is working with Uber to offer FDA-emergency use authorized, at-home COVID-19 testing kits to consumers via on-demand delivery. Individuals can now quickly access one of the most sensitive at-home COVID-19 tests on the marketi – whether they are at home, in the office or traveling.